Aglatimagene besadenovec

贝阿马基

Report date: 2026/04/08 15:31:39

Base Information

Drug NameAglatimagene besadenovec
Drug Alias NameAdV-tk therapy贝沙-阿拉替玛近重组腺病毒-胸苷激酶基因Aglatimagenum besadenovecumHSV-vectored thymidine kinase +[23] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActiondGTP(deoxyguanosine triphosphate) antagonistsGene transferenceThymidine kinase stimulants
TargetsThymidine kinasedGTP(deoxyguanosine triphosphate)
Therapy Area/IndicationsProstatic NeoplasmsPleural Effusion, MalignantCarcinoma, Non-Small-Cell Lung +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoMexico +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAdvantagene Inc
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Tiandakang Biotechnology Co LtdShenzhen Tiandakang Gene Engineering Co LtdIDEA Pharma Ltd +[5] 
Inactive CompaniesHuazhong University Of Science And Technology
Active IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[7] 
Inactive IndicationsPleural Effusion, MalignantOvarian NeoplasmsBreast Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBank